Skip to main content

Advertisement

Log in

Epidemiology of urinary bladder cancer: from tumor development to patient’s death

World Journal of Urology Aims and scope Submit manuscript

Abstract

Urinary bladder cancer (UBC) ranks ninth in worldwide cancer incidence. It is more frequent in men than in women. We review the main established/proposed factors, both environmental and genetic, associated with bladder cancer etiology and prognosis. Data were extracted from previous reviews and original articles identified from PubMed searches, reference lists, and book chapters dealing with the reviewed topics. Evaluation and consensus of both the contribution of each factor in bladder cancer burden and the appropriateness of the available evidences was done during an ad hoc meeting held during the 18th Congress of the European Society for Urological Research. Cigarette smoking and specific occupational exposures are the main known causes of UBC. Phenacetin, chlornaphazine and cyclophosphamide also increase the risk of bladder cancer. Chronic infection by Schistosoma haematobium is a cause of squamous cell carcinoma of the bladder. NAT2 slow acetylator and GSTM1 null genotypes are associated with an increased risk of this cancer. Vegetables and fresh fruits protect against this tumor. Regarding prognosis, there is little knowledge on the predictive role of environmental exposures and genetic polymorphisms on tumor recurrence and progression and patient’s death. Although active tobacco smoking is the most commonly studied factor, no definitive conclusion can be drawn from the literature. More research is needed regarding the effect of complex etiological factors in bladder carcinogenesis. Subgroup analysis according to stage, grade, and molecular features may help in identifying specific etiological and prognostic factors involved in different bladder cancer progression pathways.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Ferlay J, Bray F, Pisani P, Parkin DM (2004) GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide, version 1.0. IARC CancerBase No. 5. IARCPress, Lyon

  2. Levi F, Lucchini F, Negri E, Boyle P, La Vecchia C (2004) Cancer mortality in Europe, 1995–1999, and an overview of trends since 1960. Int J Cancer 110:155–169

    PubMed  CAS  Google Scholar 

  3. Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK (2003) Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 8:541–552

    PubMed  Google Scholar 

  4. Sant M, Aareleid T, Berrino F et al (2003) EUROCARE-3: survival of cancer patients diagnosed 1990–94-results and commentary. Ann Oncol 14(Suppl 5):V61–V118

    PubMed  Google Scholar 

  5. Wilson K, Gibson N, Willan A, Cook D (2000) Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med 160:939–944

    PubMed  CAS  Google Scholar 

  6. Zeegers MP, Tan FE, Dorant E, van Den Brandt PA (2000) The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer 89:630–639

    PubMed  CAS  Google Scholar 

  7. Silverman DT, Devesa SS, Moore LE, Rothman N (2006) Bladder cancer. In: Schottenfeld D, Fraumeni J (eds) Cancer Epidemiology and prevention, 3rd edn. Oxford University Press, New York

    Google Scholar 

  8. Fortuny J, Kogevinas M, Chang-Claude J et al (1999) Tobacco, occupation and non-transitional-cell carcinoma of the bladder: an international case-control study. Int J Cancer 80:44–46

    PubMed  CAS  Google Scholar 

  9. Brennan P, Bogillot O, Cordier S et al (2000) Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. Int J Cancer 86:289–294

    PubMed  CAS  Google Scholar 

  10. Hartge P, Silverman D, Hoover R et al (1987) Changing cigarette habits and bladder cancer risk: a case-control study. J Natl Cancer Inst 78:1119–1125

    PubMed  CAS  Google Scholar 

  11. Wynder EL, Augustine A, Kabat GC, Hebert JR (1988) Effect of the type of cigarette smoked on bladder cancer risk. Cancer 61:622–627

    PubMed  CAS  Google Scholar 

  12. López-Abente G, Gonzalez CA, Errezola M et al (1991) Tobacco smoke inhalation pattern, tobacco type, and bladder cancer in Spain. Am J Epidemiol 134:830–839

    PubMed  Google Scholar 

  13. Iscovich J, Castelletto R, Esteve J et al (1987) Tobacco smoking, occupational exposure and bladder cancer in Argentina. Int J Cancer 40:734–740

    PubMed  CAS  Google Scholar 

  14. Vineis P, Esteve J, Hartge P, Hoover R, Silverman DT, Terracini B (1988) Effects of timing and type of tobacco in cigarette-induced bladder cancer. Cancer Res 48:3849–3852

    PubMed  CAS  Google Scholar 

  15. Clavel J, Cordier S, Boccon-Gibod L, Hemon D (1989) Tobacco and bladder cancer in males: increased risk for inhalers and smokers of black tobacco. Int J Cancer 44:605–610

    PubMed  CAS  Google Scholar 

  16. De Stefani E, Correa P, Fierro L, Fontham E, Chen V, Zavala D (1991) Black tobacco, mate, and bladder cancer. A case-control study from Uruguay. Cancer 67:536–540

    PubMed  Google Scholar 

  17. Howe GR, Burch JD, Miller AB et al (1980) Tobacco use, occupation, coffee, various nutrients, and bladder cancer. J Natl Cancer Inst 64:701–713

    PubMed  CAS  Google Scholar 

  18. Morrison AS, Buring JE, Verhoek WG et al (1984) An international study of smoking and bladder cancer. J Urol 131:650–654

    PubMed  CAS  Google Scholar 

  19. Pitard A, Brennan P, Clavel J et al (2001) Cigar, pipe, and cigarette smoking and bladder cancer risk in European men. Cancer Causes Control 12:551–556

    PubMed  CAS  Google Scholar 

  20. Zeegers MP, Volovics A, Dorant E, Goldbohm RA, van den Brandt PA (2001) Alcohol consumption and bladder cancer risk: results from The Netherlands Cohort Study. Am J Epidemiol 153:38–41

    PubMed  CAS  Google Scholar 

  21. IARC Monogr Eval Carcinog Risks Hum (1991) Coffee, tea, mate, methylxanthines and methylglioxal, vol 51. IARCPress, Lyon

  22. Zeegers MP, Dorant E, Goldbohm RA, van den Brandt PA (2001) Are coffee, tea, and total fluid consumption associated with bladder cancer risk? Results from the Netherlands Cohort Study. Cancer Causes Control 12:231–238

    PubMed  CAS  Google Scholar 

  23. Sala M, Cordier S, Chang-Claude J et al (2000) Coffee consumption and bladder cancer in nonsmokers: a pooled analysis of case-control studies in European countries. Cancer Causes Control 11:925–931

    PubMed  CAS  Google Scholar 

  24. Jensen OM, Wahrendorf J, Knudsen JB, Sorensen BL (1986) The Copenhagen case-control study of bladder cancer. II. Effect of coffee and other beverages. Int J Cancer 37:651–657

    PubMed  CAS  Google Scholar 

  25. Kunze E, Chang-Claude J, Frentzel-Beyme R (1992) Life style and occupational risk factors for bladder cancer in Germany. A case-control study. Cancer 69:1776–1790

    PubMed  CAS  Google Scholar 

  26. Vena JE, Graham S, Freudenheim J et al (1993) Drinking water, fluid intake, and bladder cancer in western New York. Arch Environ Health 48:191–198

    PubMed  CAS  Google Scholar 

  27. Wilkens LR, Kadir MM, Kolonel LN, Nomura AM, Hankin JH (1996) Risk factors for lower urinary tract cancer: the role of total fluid consumption, nitrites and nitrosamines, and selected foods. Cancer Epidemiol Biomarkers Prev 5:161–166

    PubMed  CAS  Google Scholar 

  28. Michaud DS, Spiegelman D, Clinton SK et al (1999) Fluid intake and the risk of bladder cancer in men. N Engl J Med 340:1390–1397

    PubMed  CAS  Google Scholar 

  29. Slattery ML, West DW, Robison LM (1988) Fluid intake and bladder cancer in Utah. Int J Cancer 42:17–22

    PubMed  CAS  Google Scholar 

  30. Bruemmer B, White E, Vaughan TL, Cheney CL (1997) Fluid intake and the incidence of bladder cancer among middle-aged men and women in a three-county area of western Washington. Nutr Cancer 29:163–168

    PubMed  CAS  Google Scholar 

  31. Cantor KP, Lynch CF, Hildesheim ME et al (1998) Drinking water source and chlorination byproducts. I. Risk of bladder cancer. Epidemiology 9:21–28

    PubMed  CAS  Google Scholar 

  32. Geoffroy-Perez B, Cordier S (2001) Fluid consumption and the risk of bladder cancer: results of a multicenter case-control study. Int J Cancer 93:880–887

    PubMed  CAS  Google Scholar 

  33. Najem GR, Louria DB, Seebode JJ et al (1982) Life time occupation, smoking, caffeine, saccharine, hair dyes and bladder carcinogenesis. Int J Epidemiol 11:212–217

    PubMed  CAS  Google Scholar 

  34. Morgan RW, Jain MG (1974) Bladder cancer: smoking, beverages and artificial sweeteners. Can Med Assoc J 111:1067–1070

    PubMed  CAS  Google Scholar 

  35. Kessler II, Clark JP (1978) Saccharin, cyclamate, and human bladder cancer. No evidence of an association. JAMA 240:349–355

    PubMed  CAS  Google Scholar 

  36. Morrison AS, Buring JE (1980) Artificial sweeteners and cancer of the lower urinary tract. N Engl J Med 302:537–541

    PubMed  CAS  Google Scholar 

  37. Wynder EL, Stellman SD (1980) Artificial sweetener use and bladder cancer: a case-control study. Science 207:1214–1216

    PubMed  CAS  Google Scholar 

  38. Hoover RN, Strasser PH (1980) Artificial sweeteners and human bladder cancer. Preliminary results. Lancet 1:837–840

    PubMed  CAS  Google Scholar 

  39. Morrison AS, Verhoek WG, Leck I, Aoki K, Ohno Y, Obata K (1982) Artificial sweeteners and bladder cancer in Manchester, U.K., and Nagoya, Japan. Br J Cancer 45:332–336

    PubMed  CAS  Google Scholar 

  40. Moller-Jensen O, Knudsen JB, Sorensen BL, Clemmesen J (1983) Artificial sweeteners and absence of bladder cancer risk in Copenhagen. Int J Cancer 32:577–582

    PubMed  CAS  Google Scholar 

  41. IARC Monogr Eval Carcinog Risks Hum (1999) Some chemicals that cause tumors of the kidney or urinary bladder in rodents and some other substances, vol 73. IARCPress, Lyon

  42. La Vecchia C, Negri E (1996) Nutrition and bladder cancer. Cancer Causes Control 7:95–100

    PubMed  CAS  Google Scholar 

  43. Steinmaus CM, Nunez S, Smith AH (2000) Diet and bladder cancer: a meta-analysis of six dietary variables. Am J Epidemiol 151:693–702

    PubMed  CAS  Google Scholar 

  44. Augustsson K, Skog K, Jagerstad M, Dickman PW, Steineck G (1999) Dietary heterocyclic amines and cancer of the colon, rectum, bladder, and kidney: a population-based study. Lancet 353:703–707

    PubMed  CAS  Google Scholar 

  45. Bruemmer B, White E, Vaughan TL, Cheney CL (1996) Nutrient intake in relation to bladder cancer among middle-aged men and women. Am J Epidemiol 144:485–495

    PubMed  CAS  Google Scholar 

  46. Michaud DS, Spiegelman D, Clinton SK, Rimm EB, Willett WC, Giovannucci E (2000) Prospective study of dietary supplements, macronutrients, micronutrients, and risk of bladder cancer in US men. Am J Epidemiol 152:1145–1153

    PubMed  CAS  Google Scholar 

  47. Nomura A, Heilbrun LK, Morris JS, Stemmermann GN (1987) Serum selenium and the risk of cancer, by specific sites: case-control analysis of prospective data. J Natl Cancer Inst 79:103–108

    PubMed  CAS  Google Scholar 

  48. Helzlsouer KJ, Comstock GW, Morris JS (1989) Selenium, lycopene, alpha-tocopherol, beta-carotene, retinol, and subsequent bladder cancer. Cancer Res 49:6144–6148

    PubMed  CAS  Google Scholar 

  49. Zeegers MP, Goldbohm RA, Bode P, van den Brandt PA (2002) Prediagnostic toenail selenium and risk of bladder cancer. Cancer Epidemiol Biomarkers Prev 11:1292–1297

    PubMed  CAS  Google Scholar 

  50. Tripathi A, Folsom AR, Anderson KE (2002) Iowa Women’s Health Study. Risk factors for urinary bladder carcinoma in postmenopausal women. The Iowa Women’s Health Study. Cancer 95:2316–2323

    PubMed  Google Scholar 

  51. Wannamethee SG, Shaper AG, Walker M (2001) Physical activity and risk of cancer in middle-aged men. Br J Cancer 85:1311–1316

    PubMed  CAS  Google Scholar 

  52. Hennekens CH, Speizer FE, Rosner B, Bain CJ, Belanger C, Peto R (1979) Use of permanent hair dyes and cancer among registered nurses. Lancet 1:1390–1393

    PubMed  CAS  Google Scholar 

  53. Henley SJ, Thun MJ (2001) Use of permanent hair dyes and bladder-cancer risk. Int J Cancer 94:903–906

    PubMed  CAS  Google Scholar 

  54. Hartge P, Hoover R, Altman R et al (1982) Use of hair dyes and risk of bladder cancer. Cancer Res 42:4784–4787

    PubMed  CAS  Google Scholar 

  55. Claude J, Kunze E, Frentzel-Beyme R, Paczkowski K, Schneider J, Schubert H (1986) Life-style and occupational risk factors in cancer of the lower urinary tract. Am J Epidemiol 124:578–589

    PubMed  CAS  Google Scholar 

  56. Nomura A, Kolonel LN, Yoshizawa CN (1989) Smoking, alcohol, occupation, and hair dye use in cancer of the lower urinary tract. Am J Epidemiol 130:1159–1163

    PubMed  CAS  Google Scholar 

  57. Lin J, Dinney CP, Grossman HB, Wu X (2006) Personal permanent hair dye use is not associated with bladder cancer risk: evidence from a case-control study. Cancer Epidemiol Biomarkers Prev 15:1746–1749

    PubMed  CAS  Google Scholar 

  58. Kogevinas M, Fernandez F, Garcia-Closas M et al (2006) Hair dye use is not associated with risk for bladder cancer: evidence from a case-control study in Spain. Eur J Cancer 42:1448–1454

    PubMed  CAS  Google Scholar 

  59. Gago-Dominguez M, Castelao JE, Yuan JM, Yu MC, Ross RK (2001) Use of permanent hair dyes and bladder-cancer risk. Int J Cancer 91:575–579

    PubMed  CAS  Google Scholar 

  60. Piper JM, Tonascia J, Matanoski GM (1985) Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. N Engl J Méd 313:292–295

    PubMed  CAS  Google Scholar 

  61. Castelao JE, Yuan JM, Gago-Dominguez M, Yu MC, Ross RK (2000) Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 82:1364–1369

    PubMed  CAS  Google Scholar 

  62. Pommer W, Bronder E, Klimpel A, Helmert U, Greiser E, Molzahn M (1999) Urothelial cancer at different tumour sites: role of smoking and habitual intake of analgesics and laxatives. Results of the Berlin Urothelial Cancer Study. Nephrol Dial Transplant 14:2892–2897

    PubMed  CAS  Google Scholar 

  63. IARC Monogr Eval Carcinog Risks Hum (1987) Overall evaluations of carcinogenicity: an updating of IARC Monographs, suppl 7, vol 1–42. IARCPress, Lyon

  64. Derby LE, Jick H (1996) Acetaminophen and renal and bladder cancer. Epidemiology 7:358–362

    PubMed  CAS  Google Scholar 

  65. Rosenberg L, Rao RS, Palmer JR et al (1998) Transitional cell cancer of the urinary tract and renal cell cancer in relation to acetaminophen use (United States). Cancer Causes Control 9:83–88

    PubMed  CAS  Google Scholar 

  66. Steineck G, Wiholm BE, Gerhardsson de Verdier M (1995) Acetaminophen, some other drugs, some diseases and the risk of transitional cell carcinoma. A population-based case-control study. Acta Oncol 34:741–748

    PubMed  CAS  Google Scholar 

  67. Kaye JA, Myers MW, Jick H (2001) Acetaminophen and the risk of renal and bladder cancer in the general practice research database. Epidemiology 12:690–694

    PubMed  CAS  Google Scholar 

  68. Friis S, Nielsen GL, Mellemkjaer L et al (2002) Cancer risk in persons receiving prescriptions for paracetamol: a Danish cohort study. Int J Cancer 97:96–101

    PubMed  CAS  Google Scholar 

  69. Schreinemachers DM, Everson RB (1994) Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5:138–146

    PubMed  CAS  Google Scholar 

  70. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ (2000) Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 320:1642–1646

    PubMed  CAS  Google Scholar 

  71. Sørensen HT, Friis S, Norgard B et al (2003) Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 88:1687–1692

    PubMed  Google Scholar 

  72. Olsen JH, Boice JD Jr, Jensen JP, Fraumeni JF Jr (1989) Cancer among epileptic patients exposed to anticonvulsant drugs. J Natl Cancer Inst 81:803–808

    PubMed  CAS  Google Scholar 

  73. Olsen JH, Wallin H, Boice JD Jr, Rask K, Schulgen G, Fraumeni JF Jr (1993) Phenobarbital, drug metabolism, and human cancer. Cancer Epidemiol Biomarkers Prev 2:449–452

    PubMed  CAS  Google Scholar 

  74. Habel LA, Bull SA, Friedman GD (1998) Barbiturates, smoking, and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 7:1049–1050

    PubMed  CAS  Google Scholar 

  75. Castelao JE, Gago-Dominguez M, Yuan JM, Ross RK, Yu MC (2003) Phenobarbital use and bladder cancer risk. Eur J Epidemiol 18:659–664

    PubMed  CAS  Google Scholar 

  76. Miller CT, Neutel CI, Nair RC, Marrett LD, Last JM, Collins WE (1978) Relative importance of risk factors in bladder carcinogenesis. J Chronic Dis 31:51–56

    PubMed  CAS  Google Scholar 

  77. Kantor AF, Hartge P, Hoover RN, Fraumeni JF Jr (1985) Tuberculosis chemotherapy and risk of bladder cancer. Int J Epidemiol 14:182–184

    PubMed  CAS  Google Scholar 

  78. Glassroth JL, Snider DE, Comstock GW (1977) Urinary tract cancer and isoniazid. Am Rev Respir Dis 116:331–333

    PubMed  CAS  Google Scholar 

  79. Pedersen-Bjergaard J, Ersboll J, Hansen VL et al (1988) Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin’s lymphoma. N Engl J Med 318:1028–1032

    PubMed  CAS  Google Scholar 

  80. Travis LB, Curtis RE, Glimelius B et al (1995) Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin’s lymphoma. J Natl Cancer Inst 87:524–530

    PubMed  CAS  Google Scholar 

  81. Knight A, Askling J, Ekbom A (2002) Cancer incidence in a population-based cohort of patients with Wegener’s granulomatosis. Int J Cancer 100:82–85

    PubMed  CAS  Google Scholar 

  82. Golka K, Wiese A, Assennato G, Bolt HM (2004) Occupational exposure and urological cancer. World J Urol 21:382–391

    PubMed  CAS  Google Scholar 

  83. Boffetta P, Jourenkova N, Gustavsson P (1997) Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons. Cancer Causes Control 8:444–472

    PubMed  CAS  Google Scholar 

  84. Boffetta P, Silverman DT (2001) A meta-analysis of bladder cancer and diesel exhaust exposure. Epidemiology 12:125–130

    PubMed  CAS  Google Scholar 

  85. Kogevinas M, ‘t Mannetje A, Cordier S et al (2003) Occupation and bladder cancer among men in Western Europe. Cancer Causes Control 14:907–914

    PubMed  Google Scholar 

  86. Mannetje A, Kogevinas M, Chang-Claude J et al (1999) Occupation and bladder cancer in European women. Cancer Causes Control 10:209–217

    PubMed  CAS  Google Scholar 

  87. Wilkins JR 3rd, Comstock GW (1981) Source of drinking water at home and site-specific cancer incidence in Washington County, Maryland. Am J Epidemiol 114:178–190

    PubMed  Google Scholar 

  88. Cantor KP, Hoover R, Hartge P et al (1987) Bladder cancer, drinking water source, and tap water consumption: a case-control study. J Natl Cancer Inst 79:1269–1279

    PubMed  CAS  Google Scholar 

  89. McGeehin MA, Reif JS, Becher JC, Mangione EJ (1993) Case-control study of bladder cancer and water disinfection methods in Colorado. Am J Epidemiol 138:492–501

    PubMed  CAS  Google Scholar 

  90. King WD, Marrett LD (1996) Case-control study of bladder cancer and chlorination by-products in treated water (Ontario, Canada). Cancer Causes Control 7:596–604

    PubMed  CAS  Google Scholar 

  91. Villanueva CM, Cantor KP, Cordier S et al (2004) Disinfection byproducts and bladder cancer: a pooled analysis. Epidemiology 15:357–367

    PubMed  Google Scholar 

  92. Hopenhayn-Rich C, Biggs ML, Fuchs A et al (1996) Bladder cancer mortality associated with arsenic in drinking water in Argentina. Epidemiology 7:117–124

    PubMed  CAS  Google Scholar 

  93. Smith AH, Goycolea M, Haque R, Biggs ML (1998) Marked increase in bladder and lung cancer mortality in a region of Northern Chile due to arsenic in drinking water. Am J Epidemiol 147:660–669

    PubMed  CAS  Google Scholar 

  94. Chiou HY, Chiou ST, Hsu YH et al (2001) Incidence of transitional cell carcinoma and arsenic in drinking water: a follow-up study of 8,102 residents in an arseniasis-endemic area in northeastern Taiwan. Am J Epidemiol 153:411–418

    PubMed  CAS  Google Scholar 

  95. Chen YC, Su HJ, Guo YL et al (2003) Arsenic methylation and bladder cancer risk in Taiwan. Cancer Causes Control 14:303–310

    PubMed  Google Scholar 

  96. IARC Monogr Eval Carcinog Risks Hum (2004) Some drinking-water disinfectants and contaminants, including arsenic, vol 84. IARCPress, Lyon

  97. Weyer PJ, Cerhan JR, Kross BC et al (2001) Municipal drinking water nitrate level and cancer risk in older women: the Iowa Women’s Health Study. Epidemiology 12:327–338

    PubMed  CAS  Google Scholar 

  98. Ward MH, Cantor KP, Riley D, Merkle S, Lynch CF (2003) Nitrate in public water supplies and risk of bladder cancer. Epidemiology 14:183–190

    PubMed  Google Scholar 

  99. Boice JD Jr, Engholm G, Kleinerman RA et al (1988) Radiation dose and second cancer risk in patients treated for cancer of the cervix. Radiat Res 116:3–55

    PubMed  Google Scholar 

  100. Inskip PD, Monson RR, Wagoner JK et al (1990) Cancer mortality following radium treatment for uterine bleeding. Radiat Res 123:331–344

    PubMed  CAS  Google Scholar 

  101. Neugut AI, Ahsan H, Robinson E, Ennis RD (1997) Bladder carcinoma and other second malignancies after radiotherapy for prostate carcinoma. Cancer 79:1600–1604

    PubMed  CAS  Google Scholar 

  102. Brenner DJ, Curtis RE, Hall EJ, Ron E (2000) Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 88:398–406

    PubMed  CAS  Google Scholar 

  103. Piper JM, Matanoski GM, Tonascia J (1986) Bladder cancer in young women. Am J Epidemiol 123:1033–1042

    PubMed  CAS  Google Scholar 

  104. Edmonds CJ, Smith T (1986) The long-term hazards of the treatment of thyroid cancer with radioiodine. Br J Radiol 59:45–51

    PubMed  CAS  Google Scholar 

  105. Franklyn JA, Maisonneuve P, Sheppard M, Betteridge J, Boyle P (1999) Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet 353:2111–2115

    PubMed  CAS  Google Scholar 

  106. Sandler DP, Everson RB, Wilcox AJ (1985) Passive smoking in adulthood and cancer risk. Am J Epidemiol 121:37–48

    PubMed  CAS  Google Scholar 

  107. Burch JD, Rohan TE, Howe GR et al (1989) Risk of bladder cancer by source and type of tobacco exposure: a case-control study. Int J Cancer 44:622–628

    PubMed  CAS  Google Scholar 

  108. Zeegers MP, Goldbohm RA, van den Brandt PA (2002) A prospective study on active and environmental tobacco smoking and bladder cancer risk (The Netherlands). Cancer Causes Control 13:83–90

    PubMed  Google Scholar 

  109. IARC Monogr Eval Carcinog Risks Hum (1994) Schistosomes, liver flukes and Helicobacter pylory, vol 61. IARCPress, Lyon

  110. Chitsulo L, Loverde P, Engels D (2004) Schistosomiasis. Nat Rev Microbiol 2:12–13

    PubMed  CAS  Google Scholar 

  111. Kantor AF, Hartge P, Hoover RN, Narayana AS, Sullivan JW, Fraumeni JF Jr (1984) Urinary tract infection and risk of bladder cancer. Am J Epidemiol 119:510–515

    PubMed  CAS  Google Scholar 

  112. González CA, Errezola M, Izarzugaza I, et al (1991) Urinary infection, renal lithiasis and bladder cancer in Spain. Eur J Cancer 27:498–500

    PubMed  Google Scholar 

  113. La Vecchia C, Negri E, D’Avanzo B, Savoldelli R, Franceschi S (1991) Genital and urinary tract diseases and bladder cancer. Cancer Res 51:629–631

    PubMed  CAS  Google Scholar 

  114. Kjaer SK, Knudsen JB, Sorensen BL, Moller Jensen O (1989) The Copenhagen case-control study of bladder cancer. V. Review of the role of urinary-tract infection. Acta Oncol 28:631–636

    PubMed  CAS  Google Scholar 

  115. Griffiths TR, Mellon JK (2000) Human papillomavirus and urological tumours: II. Role in bladder, prostate, renal and testicular cancer. BJU Int 85:211–217

    PubMed  CAS  Google Scholar 

  116. Chow WH, Lindblad P, Gridley G et al (1997) Risk of urinary tract cancers following kidney or ureter stones. J Natl Cancer Inst 89:1453–1457

    PubMed  CAS  Google Scholar 

  117. Rothman N, Talaska G, Hayes RB et al (1997) Acidic urine pH is associated with elevated levels of free urinary benzidine and N-acetylbenzidine and urothelial cell DNA adducts in exposed workers. Cancer Epidemiol Biomarkers Prev 6:1039–1042

    PubMed  CAS  Google Scholar 

  118. Wada S, Yoshimura R, Masuda C et al (2001) Are tobacco use and urine pH indicated as risk factors for bladder carcinoma? Int J Urol 8:106–109

    PubMed  CAS  Google Scholar 

  119. Hartge P, Harvey EB, Linehan WM et al (1990) Unexplained excess risk of bladder cancer in men. J Natl Cancer Inst 82:1636–1640

    PubMed  CAS  Google Scholar 

  120. Cantor KP, Lynch CF, Johnson D (1992) Bladder cancer, parity, and age at first birth. Cancer Causes Control 3:57–62

    PubMed  CAS  Google Scholar 

  121. Pelucchi C, La Vecchia C, Negri E, Dal Maso L, Franceschi S (2002) Smoking and other risk factors for bladder cancer in women. Prev Med 35:114–120

    PubMed  Google Scholar 

  122. Fraumeni JF Jr, Thomas LB (1967) Malignant bladder tumors in a man and his three sons. J Am Med Assoc 201:507

    Google Scholar 

  123. McCullough DL, Lamma DL, McLaughlin AP 3rd, Gittes RF (1975) Familial transitional cell carcinoma of the bladder. J Urol 113:629–635

    PubMed  CAS  Google Scholar 

  124. Sharma SK, Bapna BC, Singh SM (1976) Familial profile of transitional cell carcinoma. Br J Urol 48:442

    PubMed  CAS  Google Scholar 

  125. Mahboubi AO, Ahlvin RC, Mahboubi EO (1981) Familial aggregation of urothelial carcinoma. J Urol 126:691–692

    PubMed  CAS  Google Scholar 

  126. Cartwright RA (1979) Genetic association with bladder cancer. Br Med J 2:798

    PubMed  CAS  Google Scholar 

  127. Kantor AF, Hartge P, Hoover RN, Fraumeni JF Jr (1985) Familial and environmental interactions in bladder cancer risk. Int J Cancer 35:703–706

    PubMed  CAS  Google Scholar 

  128. You XY, Chen JG, Hu YN (1990) Studies on the relation between bladder cancer and benzidine or its derived dyes in Shanghai. Br J Ind Med 47:544–552

    PubMed  CAS  Google Scholar 

  129. Kramer AA, Graham S, Burnett WS, Nasca P (1991) Familial aggregation of bladder cancer stratified by smoking status. Epidemiology 2:145–148

    PubMed  CAS  Google Scholar 

  130. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH (1994) Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 86:1600–1608

    PubMed  CAS  Google Scholar 

  131. Aben KK, Witjes JA, Schoenberg MP, Hulsbergen-van de Kaa C, Verbeek AL, Kiemeney LA (2002) Familial aggregation of urothelial cell carcinoma. Int J Cancer 98:274–278

    PubMed  CAS  Google Scholar 

  132. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K (2000) Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343:78–85

    PubMed  CAS  Google Scholar 

  133. Garcia-Closas M, Malats N, Silverman D et al (2005) NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 366:649–659

    PubMed  CAS  Google Scholar 

  134. Green J, Banks E, Berrington A, Darby S, Deo H, Newton R (2000) N-acetyltransferase 2 and bladder cancer: an overview and consideration of the evidence for gene-environment interaction. Br J Cancer 83:412–417

    PubMed  CAS  Google Scholar 

  135. Cascorbi I, Roots I, Brockmoller J (2001) Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10. Cancer Res 61:5051–5056

    PubMed  CAS  Google Scholar 

  136. Hung RJ, Boffetta P, Brennan P et al (2004) GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population. Int J Cancer 110:598–604

    PubMed  CAS  Google Scholar 

  137. Brockmoller J, Cascorbi I, Kerb R, Roots I (1996) Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 56:3915–3925

    PubMed  CAS  Google Scholar 

  138. Kempkes M, Golka K, Reich S, Reckwitz T, Bolt HM (1996) Glutathione S-transferase GSTM1 and GSTT1 null genotypes as potential risk factors for urothelial cancer of the bladder. Arch Toxicol 71:123–126

    PubMed  CAS  Google Scholar 

  139. Harries LW, Stubbins MJ, Forman D, Howard GC, Wolf CR (1997) Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 18:641–644

    PubMed  CAS  Google Scholar 

  140. Toruner GA, Akyerli C, Ucar A et al (2001) Polymorphisms of glutathione S-transferase genes (GSTM1, GSTP1 and GSTT1) and bladder cancer susceptibility in the Turkish population. Arch Toxicol 75:459–464

    PubMed  CAS  Google Scholar 

  141. Giannakopoulos X, Charalabopoulos K, Baltogiannis D et al (2002) The role of N-acetyltransferase-2 and glutathione S-transferase on the risk and aggressiveness of bladder cancer. Anticancer Res 22:3801–3804

    PubMed  Google Scholar 

  142. Kim WJ, Kim H, Kim CH et al (2002) GSTT1-null genotype is a protective factor against bladder cancer. Urology 60:913–918

    PubMed  Google Scholar 

  143. Lee SJ, Cho SH, Park SK et al (2002) Combined effect of glutathione S-transferase M1 and T1 genotypes on bladder cancer risk. Cancer Lett 177:173–179

    PubMed  CAS  Google Scholar 

  144. Ozawa S, Katoh T, Inatomi H et al (2003) Association of genotypes of carcinogen-activating enzymes, phenol sulfotransferase SULT1A1 (ST1A3) and arylamine N-acetyltransferase NAT2, with urothelial cancer in a Japanese population. Cancer Lett 202:61–69

    Google Scholar 

  145. Zheng L, Wang Y, Schabath MB, Grossman HB, Wu X (2003) Sulfotransferase 1A1 (SULT1A1) polymorphism and bladder cancer risk: a case-control study. Cancer Lett 202:61–69

    PubMed  CAS  Google Scholar 

  146. Lee SW, Jang IJ, Shin SG et al (1994) CYP1A2 activity as a risk factor for bladder cancer. J Korean Med Sci 9:482–489

    PubMed  CAS  Google Scholar 

  147. Anwar WA, Abdel-Rahman SZ, El-Zein RA, Mostafa HM, Au WW (1996) Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients. Carcinogenesis 17:1923–1929

    PubMed  CAS  Google Scholar 

  148. Choi JY, Lee KM, Cho SH et al (2003) CYP2E1 and NQO1 genotypes, smoking and bladder cancer. Pharmacogenetics 13:349–355

    PubMed  CAS  Google Scholar 

  149. Kelsey KT, Park S, Nelson HH, Karagas MR (2004) A population-based case-control study of the XRCC1 Arg399Gln polymorphism and susceptibility to bladder cancer. Cancer Epidemiol Biomarkers Prev 13:1337–1341

    PubMed  CAS  Google Scholar 

  150. Matullo G, Guarrera S, Sacerdote C et al (2005) Polymorphisms/haplotypes in DNA repair genes and smoking: a bladder cancer case-control study. Cancer Epidemiol Biomarkers Prev 14:2569–2578

    PubMed  CAS  Google Scholar 

  151. Garcia-Closas M, Malats N, Real FX et al (2006) Genetic variation in the nucleotide excision repair pathway and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 15:536–542

    PubMed  CAS  Google Scholar 

  152. Wu X, Gu J, Grossman HB et al (2006) Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet 78:464–479

    PubMed  CAS  Google Scholar 

  153. Mohrenweiser HW, Wilson DM 3rd, Jones IM (2003) Challenges and complexities in estimating both the functional impact and the disease risk associated with the extensive genetic variation in human DNA repair genes. Mutat Res 526:93–125

    PubMed  CAS  Google Scholar 

  154. Michalek AM, Cummings KM, Pontes JE (1985) Cigarette smoking, tumor recurrence, and survival from bladder cancer. Prev Med 14:92–98

    PubMed  CAS  Google Scholar 

  155. Carpenter AA (1989) Clinical experience with transitional cell carcinoma of the bladder with special reference to smoking. J Urol 141:527–528

    PubMed  CAS  Google Scholar 

  156. Allard P, Fradet Y, Tetu B, Bernard P (1995) Tumor-associated antigens as prognostic factors for recurrence in 382 patients with primary transitional cell carcinoma of the bladder. Clin Cancer Res 1:1195–1202

    PubMed  CAS  Google Scholar 

  157. Raitanen MP, Tammela TL (1995) Impact of tumour grade, stage, number and size, smoking habits and sex on the recurrence rate and disease-free interval in patients with transitional cell carcinoma of the bladder. Ann Chir Gynaecol 84:37–41

    PubMed  CAS  Google Scholar 

  158. Fleshner N, Garland J, Moadel A et al (1999) Influence of smoking status on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma of the bladder. Cancer 86:2337–2345

    PubMed  CAS  Google Scholar 

  159. Busto Catanon L, Sanchez Merino JM, Picallo Sanchez JA, Gelabert Mas A (2001) Clinical prognostic factors in superficial cancer of the urinary bladder. Arch Esp Urol 54:131–138

    PubMed  CAS  Google Scholar 

  160. Schmitz-Dräger BJ, Kushima M, Goebell P et al (1997) p53 and MDM2 in the development and progression of bladder cancer. Eur Urol 32:487–493

    PubMed  Google Scholar 

  161. Takashi M, Murase T, Mizuno S, Hamajima N, Ohno Y (1987) Multivariate evaluation of prognostic determinants in bladder cancer patients. Urol Int 42:368–374

    PubMed  CAS  Google Scholar 

  162. Wakai K, Ohno Y, Obata K, Aoki K (1993) Prognostic significance of selected lifestyle factors in urinary bladder cancer. Jpn J Cancer Res 84:1223–1229

    PubMed  CAS  Google Scholar 

  163. Anthony HM, Thomas GM (1970) Bladder tumours and smoking. Int J Cancer 5:266–272

    PubMed  CAS  Google Scholar 

  164. Thrasher JB, Frazier HA, Robertson JE, Dodge RK, Paulson DF (1994) Clinical variables which serve as predictors of cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer 73:1708–1715

    PubMed  CAS  Google Scholar 

  165. Raitanen MP, Nieminen P, Tammela TL (1995) Impact of tumour grade, stage, number and size, and smoking and sex, on survival in patients with transitional cell carcinoma of the bladder. Br J Urol 76:470–474

    PubMed  CAS  Google Scholar 

  166. Aveyard P, Adab P, Cheng KK, Wallace DM, Hey K, Murphy MF (2002) Does smoking status influence the prognosis of bladder cancer? A systematic review. BJU Int 90:228–239

    PubMed  CAS  Google Scholar 

  167. Koch M, Hill GB, McPhee MS (1986) Factors affecting recurrence rates in superficial bladder cancer. J Natl Cancer Inst 76:1025–1029

    PubMed  CAS  Google Scholar 

  168. Donat SM, Bayuga S, Herr HW, Berwick M (2003) Fluid intake and the risk of tumor recurrence in patients with superficial bladder cancer. J Urol 170:1777–1780

    PubMed  Google Scholar 

  169. Cheng L, Neumann RM, Weaver AL, Spotts BE, Bostwick DG (1999) Predicting cancer progression in patients with stage T1 bladder carcinoma. J Clin Oncol 17:3182–3187

    PubMed  CAS  Google Scholar 

  170. Jacobs EJ, Henion AK, Briggs PJ et al (2002) Vitamin C and vitamin E supplement use and bladder cancer mortality in a large cohort of US men and women. Am J Epidemiol 156:1002–1010

    PubMed  Google Scholar 

  171. Michalek AM, Cummings KM, Phelan J (1987) Vitamin A and tumor recurrence in bladder cancer. Nutr Cancer 9:143–146

    PubMed  CAS  Google Scholar 

  172. Sheehy OE, Zhao SZ, Raymoundo AL, Miller B, Aprikian AG, Lelorier J (2003) Celecoxib associated with reduced risk of superficial bladder cancer. ASCO Annual Meeting. Abstract 1539

  173. Lopez-Beltran A, Escudero AL, Vicioso L, Munoz E, Carrasco JC (1996) Human papillomavirus DNA as a factor determining the survival of bladder cancer patients. Br J Cancer 73:124–127

    PubMed  CAS  Google Scholar 

  174. Pycha A, Mian C, Posch B et al (1999) Numerical chromosomal aberrations in muscle invasive squamous cell and transitional cell cancer of the urinary bladder: an alternative to classic prognostic indicators? Urology 53:1005–1010

    PubMed  CAS  Google Scholar 

  175. Cartwright RA, Glashan RW, Rogers HJ et al (1982) Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet 2:842–845

    PubMed  CAS  Google Scholar 

  176. Hanssen HP, Agarwal DP, Goedde HW et al (1985) Association of N-acetyltransferase polymorphism and environmental factors with bladder carcinogenesis. Study in a north German population. Eur Urol 11:263–266

    PubMed  CAS  Google Scholar 

  177. Mommsen S, Aagaard J (1986) Susceptibility in urinary bladder cancer: acetyltransferase phenotypes and related risk factors. Cancer Lett 32:199–205

    PubMed  CAS  Google Scholar 

  178. Inatomi H, Katoh T, Kawamoto T, Matsumoto T (1999) NAT2 gene polymorphism as a possible marker for susceptibility to bladder cancer in Japanese. Int J Urol 6:446–454

    PubMed  CAS  Google Scholar 

  179. Jong Jeong H, Jin Kim H, Young Seo I et al (2003) Association between glutathione S-transferase M1 and T1 polymorphisms and increased risk for bladder cancer in Korean smokers. Cancer Lett 202:193–9199

    PubMed  Google Scholar 

  180. Marsh HP, Haldar NA, Bunce M et al (2003) Polymorphisms in tumour necrosis factor (TNF) are associated with risk of bladder cancer and grade of tumour at presentation. Br J Cancer 89:1096–1101

    PubMed  CAS  Google Scholar 

  181. Zhang X, Ma X, Zhu QG, Li LC, Chen Z, Ye ZQ (2003) Association between a C/A single nucleotide polymorphism of the E-cadherin gene promoter and transitional cell carcinoma of the bladder. J Urol 170:1379–1382

    PubMed  CAS  Google Scholar 

  182. van Gils CH, Conway K, Li Y, Taylor JA (2002) HRAS1 variable number of tandem repeats polymorphism and risk of bladder cancer. Int J Cancer 100:414–418

    PubMed  Google Scholar 

  183. Tsukino H, Kuroda Y, Nakao H et al (2004) Cytochrome P450 (CYP) 1A2, sulfotransferase (SULT) 1A1, and N-acetyltransferase (NAT) 2 polymorphisms and susceptibility to urothelial cancer. J Cancer Res Clin Oncol 130:99–106

    PubMed  CAS  Google Scholar 

  184. Ryk C, Berggren P, Kumar R et al (2005) Influence of GSTM1, GSTT1, GSTP1 and NAT2 genotypes on the p53 mutational spectrum in bladder tumours. Int J Cancer 113:761–768

    PubMed  CAS  Google Scholar 

  185. Basu S, Brown JE, Flannigan GM et al (2004) Immunohistochemical analysis of NAD(P)H:quinone oxidoreductase and NADPH cytochrome P450 reductase in human superficial bladder tumours: relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy. Int J Cancer 109:703–709

    PubMed  CAS  Google Scholar 

  186. Fleming CM, Kaisary A, Wilkinson GR, Smith P, Branch RA (1992) The ability to 4-hydroxylate debrisoquine is related to recurrence of bladder cancer. Pharmacogenetics 2:128–134

    PubMed  CAS  Google Scholar 

  187. Sakano S, Berggren P, Kumar R et al (2003) Clinical course of bladder neoplasms and single nucleotide polymorphisms in the CDKN2A gene. Int J Cancer 104:98–103

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors thank the International Bladder Cancer Network (IBCN) for generating a stimulating environment for discussion. This work was supported in part by the Fondo de Investigación Sanitaria (grants 96/1998-01, 00/0745, G03/160, G03/174, C03/09, C03/10, PI051436).

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Bernd J. Schmitz-Dräger or Núria Malats.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Murta-Nascimento, C., Schmitz-Dräger, B.J., Zeegers, M. . et al. Epidemiology of urinary bladder cancer: from tumor development to patient’s death. World J Urol 25, 285–295 (2007). https://doi.org/10.1007/s00345-007-0168-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-007-0168-5

Keywords

Navigation